10/517240

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

371 of PCT/AU2003/000716

Applicant

Eric Francis Morand et al.

International

Filing Date

June 6, 2003

TC/A.U.

Examiner

Title

Napththalene Derivatives Which Inhibit the Cytokine or Biological

Activity of Macrophage Migration Inhibitory Factor (MIF)

Docket No.

BDW002

Customer No.:

20786

Mail Stop PCT

December 7, 2004

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants cite the information on the attached Form PTO-1449, "List of Information Disclosed by Applicant," pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. Applicants have enclosed a copy of each foreign patent document and other non-United States patent references cited therein.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

Madeline I. Johnston, Esq.

Reg. No. 36,174

King & Spalding LLP 191 Peachtree Street 45th Floor

Atlanta, GA 30303-1763 Tel.: (404) 572-4600

Fax: (404) 572-5145

3637655_1.DOC

FORM PTO-1449, Adapted

LIST OF INFORMATION DISCLOSED BY APPLICANT 17240

(Use several sheets if necessary) ATTY. DOCKET NO. SERIAL NO. INTERNATIONAL FILING DATE **BDW002** December 6, 2003 APPLICANT GROUP Eric Francis Morand et al. U.S. PATENT DOCUMENTS EXAMINER DOCUMENT NUMBER DATE NAME SUBCLASS CLASS FILING DATE INITIAL IF APPROPRIATE AA 5,208,344 05/04/93 Kreft et al. AB 01/28/92 5,084,575 Kreft et al. AC 4,910,208 03/20/90 Misra AD 3,958,012 05/18/76 Fried et al. **AE** 3,969,415 07/13/76 Galantay AF 3,978,124 08/31/76 Fried et al. AG 3,994,968 11/30/76 Alvarez AH 3,998,966 12/21/76 Fried et al. ΑI 4,009,197 02/22/77 Fried et al. AJ 09/09/75 3,904,682 Fried et al.

Al	M 5,268,458	12/07/93	Springer et al.			
Aì	N 6,420,375	07/16/02	Aono et al.			
		F	OREIGN PATEN	T DOCUMENTS		
	DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANSI	LATION
		1			YES	NO.
AC	0 6809942	01/14/70	NL	Syntex Corp.		
AI	P 2051012	04/20/72	DE	Syntex Corp.		
AC	Q 2258349	06/07/93	DE	Sandoz		
EXAMINER				DATE CONSIDERED		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

AK

3,935,273

3,562,336

01/27/76

02/09/71

Fried et al.

Nelson

Sheet 2 of 4

FORM PTO-1449, Adapted

LIST OF INFORMATION DISCLOSED BY APPLICANTS 17240

(Use several sheets if necessary)

BDW002 APPLICANT		SERIAL NO.		December 6, 2003 GROUP										
								Eric Francis Mo	rand et al.					
										F	OREIGN PA	TENT DOCUMENTS		
41	DOCUMENT NUMBER	DATE	COUNTRY	NAME	TRANS	LATION								
	DOCUMENT NUMBER	DAIL		NAVE	YES	NO.								
AR	62-103074	05/13/87	JP	Hamari Yakuhin Kogyo KK										
AS	63-203631	08/23/88	JР	Nippon Kayaku Co. Ltd.		-								
AT	279466 B1	08/24/88	EP	Warner-Lambert Co.										
AU	284359 B1	09/28/88	EP	Takeda Chemical Industries, Ltd.										
AV	286944 B1	10/19/88	EP	Enichem Synthesis S.p.A.										
AW	301813 B1	02/01/89	EP	American Home Products Corp.										
AX	372385 A2	06/13/90	EP	F. Hoffmann-La Roche AG										
AY	91/08744 A1	06/27/91	wo	Abbott Laboratories										
AZ	96/04267 A1	02/15/96	wo	Laboratorios Menarini S.A.										
ВА	97/31006 A1	08/28/97	wo	Glycomed Inc.										
ВВ	97/30992 A1	08/28/77	wo	Bristol-Myers Squibb Co.										
ВС	2329298	12/20/73	DE	Bottus										
BD	2442305	03/13/75	DT	Beecham Group Ltd.										
BE	7512107	01/30/76	NL	Syntex Corp.										
		1				1								

Grelan Pharmaceut Co. Ltd.

Nycomed Amersham PLC

Eli Lilly and Co.

ΒI 2150848 A1 12/01/00 ES Laboratorios Menarini, S.A.

EP

WO

EP

11/09/77 JP

01/14/98

01/14/99

06/21/01 WO 01/44172 A1 Axys Pharaceuticals, Inc. 01076063 03/22/89 JР Dainichiseika Color and Chemicals

10/31/84 Merck Frosst Canada, Inc. **EXAMINER** DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BF

BG

BH

BJ

BK

BL

52-133962

0818453 B1

99/01768 A1

123543

FORM PTO-1449, Adapted

LIST OF INFORMATION DISCLOSED BY APPLICANT 10/517240

	(00000	vertal sheets if necessary,				
ATTY. DOCKET NO. SERIAL NO.		INTERNATIONAL FILING DATE				
BDW002		December 6, 2003				
APPLICANT		GROUP				
Eric Francis Morand	et al.					
		luding Author, Title, Date, Pertinent Pages, Etc.)				
ВМ	Bosca et al., "A Photophysical and Metabolite of the Phototoxic Nons Photobiology, Vol 71, No. 2, pgs.	Photochemical Study of 6-Methoxy-2-Napthylacetic Acid, the Major teroidal Aniinflammatory Drug Nabumetone", 2000, Photochemistry and 173-177				
BN	Prabhakar et al., "Synthesis and Biological Activity of Novel Thiazolidinediones", 1998, Bioorganic and Medicinal Chemistry Letters, Vol. 8, No. 19, pgs. 2725-2730					
ВО	Bosca et al., "New Photodegradation Pathways for Naproxen, a Phototoxic Nonsteroidal Antiinflammatory Drug", 1990, Preliminary Note in Journal of Photochemistry and Photobiology, Vol. 54, No. 1, pgs. 131-134					
BP	Hiyama et al., "A Facile, Practical Synthesis of 2-(6-Methoxy-2-Naphthyl)propenoic Acid", 1990, Bulletin of the Chemical Society of Japan, Vol. 63, No. 2, pgs. 640-642					
BQ	Harusawa et al., "A New Synthesis of Some Non-steroidal Anti-inflammatory Agents via Cyanophosphates, 1984, Synthetic Communications, Vol. 14, No. 14, pgs. 1365-1371					
BR	Ray et al., "High-Performance Liquid Chromatographic Determination of a New Anti-inflammatory Agent, Nabumetone, and its Major Metabolite in Plasma Using Fluorimetric Detection", 1984, Note in Journal of Chromatography, Vol. 336, No. 1, pgs. 234-238					
BS	Cavrini et al., "Synthesis of Deriva Farmaco, Edizione Scientifica, Vol	tives of 2-Methoxynaphthalene as Potential Antiinflammatories", 1982, 1982, No. 3, pgs. 171-178				
ВТ		phthyl)Butan-2-One and Related Analogues, a Novel Structural Class of 078, Journal of Medicinal Chemistry, Vol 21, No. 12, pgs. 1260-1264				
BU	STN FILE CA Abstract No. 91:91390 and Tetrahedron Letters, 1978, Vol. 52, pgs. 5183-5186					
BV	STN FILE CA Abstract No. 89:6137 and Kametani et al., 1987, Vol. 98, No. 2, pgs. 146-152					
BW	STN FILE CA Abstract No. 77:114208 and Journal of Heterocyclic Chemistry, 1972, Vol. 9, No. 4, pgs. 805-811					
BX	STN FILE CA Abstract No. 71:81 1730	118 and Australian Journal of Chemistry, 1969, Vol. 22, No. 8, pgs. 1721-				
BY	STN FILE CA Abstract No. 67:799	9 and Journal of Pharmaceutical Sciences, 1967, Vol. 56, No. 8, pgs. 993-				
EXAMINER		DATE CONSIDERED .				
EXAMINER: Initial	if reference considered, whether or not cit	ation is in conformance with MPEP 609; Draw line through citation if not in				
	onsidered. Include copy of this form with					

FORM PTO-1449, Adapted

ATTY. DOCKET NO.

BDW002

APPLICANT

LIST OF INFORMATION DISCLOSED BY APPLICANT (Use several sheets if necessary) 10/5.17240 SERIAL NO. INTERNATIONAL FILING DATE December 6, 2003 GROUP et al.

Eric Francis Morai	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
BZ	STN FILE CA Abstract No. 64:3950 and Australian Journal of Chemistry, 1965, Vol. 18, No. 9, pgs. 1351-1364
CA	STN FILE CA Abstract No. 57:10708 and Journal of the American Chemical Society, 1962, Vol. 84, pgs. 859-862
СВ	STN FILE CA Abstract No. 51:17182 and Chem. Listy, 1956, Vol. 50, pgs. 1610-1616
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.